Tenofovir Disoproxil Fumarate Tablets 300 mg
Products from producer
In stock
Reconfirm the price with seller
- Customer pickup,
- Courier
- In detail
Products of other enterprises
Technical characteristics
- BrandTenofovir Disoproxil Fumarate
- Dosage formPills
- Product NameTenofovir Disoproxil Fumarate Tablets 300 mg
- Product TypeTablets
- Strength150mg , 200mg , 250mg , 300mg
Description
In order to meet the medical industry standards, these tablets are finely processed using superior quality ingredients under the strict supervision of our diligent professionals. We are providing this range in tamper proof packaging to ensure safe transit.
Features:
Supplied As:
150mg , 200mg , 250mg , 300mg
Overdose:
If tenofovir is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention
Precaution And Warning:
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) were reported with the use of nucleoside analogs in combination with other antiretrovirals.
Severe acute exacerbations of HBV have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including tenofovir. Monitor hepatic function closely with clinical and laboratory follow-up for at least several months in patients who discontinue tenofovir. If appropriate, resumption of anti-hepatitis B therapy may be warranted.
Pregnancy
Features:
- Accurate composition
- Precise pH value
- Longer shelf life
Supplied As:
150mg , 200mg , 250mg , 300mg
Overdose:
If tenofovir is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention
Precaution And Warning:
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) were reported with the use of nucleoside analogs in combination with other antiretrovirals.
Severe acute exacerbations of HBV have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including tenofovir. Monitor hepatic function closely with clinical and laboratory follow-up for at least several months in patients who discontinue tenofovir. If appropriate, resumption of anti-hepatitis B therapy may be warranted.
Pregnancy
Contact the seller
Tenofovir Disoproxil Fumarate Tablets 300 mg